TrialESMO open2023

Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis.

J Hyung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.